MedTrace Logo

Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.

NCT00138983 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2006-11-29

No results posted yet for this study

Summary

The purpose of this study is to determine wich treatment is the most effective in prevention of glucocorticoid-induced osteoporosis in patients with rheumatic diseases. The STOP-study: a randomized placebo controlled trial with alendronate versus alfacalcidol.

Conditions

  • Rheumatoid Arthritis
  • Polymyalgia Rheumatica
  • Giant Cell Arteritis
  • Polymyositis
  • Wegener's Granulomatosis

Interventions

DRUG

Alendronate versus alfacalcidol (1-alpha OH vitamin D)

Sponsors & Collaborators

  • Dutch Health Care Insurance Board

    collaborator OTHER

  • UMC Utrecht

    lead OTHER

Principal Investigators

  • J.W.J. Bijslma, Prof. · UMC Utrecht

  • R.N.J.T.L. de Nijs, MD · UMC Utrecht

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-05-31
Completion
2003-11-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00138983 on ClinicalTrials.gov